CLINICAL TRIAL: METFORMIN MITIGATION OF ANTIPSYCHOTIC-INDUCED METABOLIC DYSREGUL

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究将评价二甲双胍（一种口服降糖药）预防与使用抗精神病药相关的代谢和生理变化。我们将招募40名患有严重广泛性精神疾病（SPMI）的儿童和青少年，这些儿童和青少年有最低限度暴露于第二代抗精神病药物（SGA）的病史。受试者将接受12周的二甲双胍和新启动的SGA治疗，或仅接受新启动的SGA治疗。所有受试者将在每次访视时接受健康生活方式指导。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will evaluate metformin, an oral antihyperglycemic agent, for the prevention of metabolic and physiological changes associated with the use of antipsychotics. We will recruit 40 children and adolescents with a serious pervasive mental illness (SPMI) that have a history of minimal exposure to 2nd generation antipsychotic (SGA) medication. Participants will receive 12 weeks of treatment with either both metformin and the newly initiated SGA, or only the newly initiated SGA. All subjects will receive healthy lifestyle guidance at each visit.